Fulcrum Therapeutics announced it is discontinuing its pociredir program for sickle cell disease after the FDA raised serious safety concerns linked to a high risk of secondary blood cancers. The FDA's decision was influenced by similar risks found with another drug in the same class, leading to no viable path for regulatory approval. Following this announcement, Fulcrum's stock price dropped sharply by over 50%. Investors and affected parties are being invited to join a securities investigation by Kaplan Fox & Kilsheimer LLP into potential violations related to this matter.
Yili Group held a sustainability forum on August 2, 2026, during the World Dairy Industry Conference in Hohhot, China, gathering over 200 global leaders to discuss sustainable development in dairy farming beyond 2030. The event highlighted Yili's lea...
Yili Group organized a Sustainability Forum during the 2026 World Dairy Industry Conference in Hohhot, China, gathering over 200 international leaders to promote sustainable development in the dairy sector beyond 2030. The event highlighted Yili's le...
Ray Dalio favors NVIDIA as the top AI chip stock due to its strong cash flow, reasonable valuation, and durable growth in AI infrastructure. NVIDIA reported $81.6 billion revenue last quarter, with a forward P/E of 23 and $48.55 billion free cash flo...
Bitcoin ETFs saw inflows of about $853.5 million last week, the highest since mid-April, driven mainly by BlackRock's IBIT fund which captured over 80% of the inflows. Fidelity's FBTC also contributed significantly. Ether ETFs extended their winning ...
Alvopetro Energy Ltd reported a 26% year-over-year increase in average sales volumes to 3,067 barrels of oil equivalent per day in Q2 2026, driven by higher production and stronger commodity prices. The realized natural gas price reached nearly $11 p...
